Metformin in prostate cancer: Two for the price of one

A. Clements, B. Gao, S. H O Yeap, M. K Y Wong, S. S. Ali, H. Gurney

Research output: Contribution to journalReview articleResearchpeer-review

Abstract

Background: Androgen deprivation therapy (ADT) for prostate cancer treatment induces a metabolic syndrome, which may contribute to non-cancer-related morbidity and mortality. Metformin may abrogate these effects. Additionally, metformin has potential antineoplastic activity in various malignancies including prostate cancer. Materials and methods: A literature review using PubMed with the keywordsAMPK, androgen deprivation therapy, insulin resistance, metabolic syndrome, metformin and prostate cancer was undertaken. Results: This overview will look at the current evidence linking ADT and metabolic syndrome while discussing ongoing clinical trials under way assessing the effectiveness of metformin in abrogating these effects. The potential antineoplastic activity of metformin, mediated by multiple proposed mechanisms based on evidence from preclinical and clinical studies, will also be elucidated in this review. Conclusions: Overall available data support the potential dual benefit of metformin on ADT-induced metabolic syndrome and in its antineoplastic activity in prostate cancer, justifying the need for ongoing clinical trials to confirm these effects as the evidence currently available for standard practice is lacking.

LanguageEnglish
Article numbermdr037
Pages2556-2560
Number of pages5
JournalAnnals of Oncology
Volume22
Issue number12
DOIs
Publication statusPublished - Dec 2011
Externally publishedYes

Fingerprint

Metformin
Prostatic Neoplasms
Androgens
Antineoplastic Agents
Clinical Trials
Therapeutics
PubMed
Insulin Resistance
Morbidity
Mortality
Neoplasms

Cite this

Clements, A., Gao, B., Yeap, S. H. O., Wong, M. K. Y., Ali, S. S., & Gurney, H. (2011). Metformin in prostate cancer: Two for the price of one. Annals of Oncology, 22(12), 2556-2560. [mdr037]. https://doi.org/10.1093/annonc/mdr037
Clements, A. ; Gao, B. ; Yeap, S. H O ; Wong, M. K Y ; Ali, S. S. ; Gurney, H. / Metformin in prostate cancer : Two for the price of one. In: Annals of Oncology. 2011 ; Vol. 22, No. 12. pp. 2556-2560.
@article{be5c2354d6b8414ca503ccd1386991a8,
title = "Metformin in prostate cancer: Two for the price of one",
abstract = "Background: Androgen deprivation therapy (ADT) for prostate cancer treatment induces a metabolic syndrome, which may contribute to non-cancer-related morbidity and mortality. Metformin may abrogate these effects. Additionally, metformin has potential antineoplastic activity in various malignancies including prostate cancer. Materials and methods: A literature review using PubMed with the keywordsAMPK, androgen deprivation therapy, insulin resistance, metabolic syndrome, metformin and prostate cancer was undertaken. Results: This overview will look at the current evidence linking ADT and metabolic syndrome while discussing ongoing clinical trials under way assessing the effectiveness of metformin in abrogating these effects. The potential antineoplastic activity of metformin, mediated by multiple proposed mechanisms based on evidence from preclinical and clinical studies, will also be elucidated in this review. Conclusions: Overall available data support the potential dual benefit of metformin on ADT-induced metabolic syndrome and in its antineoplastic activity in prostate cancer, justifying the need for ongoing clinical trials to confirm these effects as the evidence currently available for standard practice is lacking.",
author = "A. Clements and B. Gao and Yeap, {S. H O} and Wong, {M. K Y} and Ali, {S. S.} and H. Gurney",
year = "2011",
month = "12",
doi = "10.1093/annonc/mdr037",
language = "English",
volume = "22",
pages = "2556--2560",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "OXFORD UNIV PRESS INC",
number = "12",

}

Clements, A, Gao, B, Yeap, SHO, Wong, MKY, Ali, SS & Gurney, H 2011, 'Metformin in prostate cancer: Two for the price of one', Annals of Oncology, vol. 22, no. 12, mdr037, pp. 2556-2560. https://doi.org/10.1093/annonc/mdr037

Metformin in prostate cancer : Two for the price of one. / Clements, A.; Gao, B.; Yeap, S. H O; Wong, M. K Y; Ali, S. S.; Gurney, H.

In: Annals of Oncology, Vol. 22, No. 12, mdr037, 12.2011, p. 2556-2560.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Metformin in prostate cancer

T2 - Annals of Oncology

AU - Clements, A.

AU - Gao, B.

AU - Yeap, S. H O

AU - Wong, M. K Y

AU - Ali, S. S.

AU - Gurney, H.

PY - 2011/12

Y1 - 2011/12

N2 - Background: Androgen deprivation therapy (ADT) for prostate cancer treatment induces a metabolic syndrome, which may contribute to non-cancer-related morbidity and mortality. Metformin may abrogate these effects. Additionally, metformin has potential antineoplastic activity in various malignancies including prostate cancer. Materials and methods: A literature review using PubMed with the keywordsAMPK, androgen deprivation therapy, insulin resistance, metabolic syndrome, metformin and prostate cancer was undertaken. Results: This overview will look at the current evidence linking ADT and metabolic syndrome while discussing ongoing clinical trials under way assessing the effectiveness of metformin in abrogating these effects. The potential antineoplastic activity of metformin, mediated by multiple proposed mechanisms based on evidence from preclinical and clinical studies, will also be elucidated in this review. Conclusions: Overall available data support the potential dual benefit of metformin on ADT-induced metabolic syndrome and in its antineoplastic activity in prostate cancer, justifying the need for ongoing clinical trials to confirm these effects as the evidence currently available for standard practice is lacking.

AB - Background: Androgen deprivation therapy (ADT) for prostate cancer treatment induces a metabolic syndrome, which may contribute to non-cancer-related morbidity and mortality. Metformin may abrogate these effects. Additionally, metformin has potential antineoplastic activity in various malignancies including prostate cancer. Materials and methods: A literature review using PubMed with the keywordsAMPK, androgen deprivation therapy, insulin resistance, metabolic syndrome, metformin and prostate cancer was undertaken. Results: This overview will look at the current evidence linking ADT and metabolic syndrome while discussing ongoing clinical trials under way assessing the effectiveness of metformin in abrogating these effects. The potential antineoplastic activity of metformin, mediated by multiple proposed mechanisms based on evidence from preclinical and clinical studies, will also be elucidated in this review. Conclusions: Overall available data support the potential dual benefit of metformin on ADT-induced metabolic syndrome and in its antineoplastic activity in prostate cancer, justifying the need for ongoing clinical trials to confirm these effects as the evidence currently available for standard practice is lacking.

UR - http://www.scopus.com/inward/record.url?scp=80053479556&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdr037

DO - 10.1093/annonc/mdr037

M3 - Review article

VL - 22

SP - 2556

EP - 2560

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 12

M1 - mdr037

ER -

Clements A, Gao B, Yeap SHO, Wong MKY, Ali SS, Gurney H. Metformin in prostate cancer: Two for the price of one. Annals of Oncology. 2011 Dec;22(12):2556-2560. mdr037. https://doi.org/10.1093/annonc/mdr037